Given the critical role of AMPK in regulating NAFLD, our findings suggest that targeting the deacetylation of LKB1 by tranilast represents a promising therapeutic strategy for metabolic liver diseases. Here, PRKAA1 is linked to metabolic dysfunction-associated steatotic liver disease.